ASTMH 2016

American Society of Tropical Medicine and Hygiene (ASTMH), 65th Annual Meeting

November 13-17, 2016
Atlanta, Georgia USA

DNDi presented in symposia on sleeping sickness and Chagas disease, they also co-authored poster presentations on filarial diseases.

 

Download DNDi @ ASTMH 2016

DNDi Symposia

Approaches, advances and needs for the elimination of human African trypanosomiasis (HAT)

Date: November 15
Chair: Gerardo Priotto, Department of Control of Neglected Tropical Diseases, WHO
Co-chair: Crispin Lumbala, PNLTHA

How can we achieve HAT elimination by 2020?
Gerardo Priotto, Department of Control of Neglected Tropical Diseases, WHO
Diagnosis of HAT: New tools in a changing context
Veerle Lejon, Institut de Recherche pour le Développement
Clinical development of new oral treatments for HAT
Antoine Tarral, DNDi
Human African Trypanosomiasis – A bio-centric hit to lead approach to identify new lead series
Thierry Diagana, Head of the Novartis Institute for Tropical Diseases

 

DNDi Symposia

Recent advances in the development of new treatments for chronic Chagas disease

Date: November 15
Chair: Sergio Sosa Estani Director, Fatala Chaben Institute, Argentina
Co-chair: Isabela Ribero, Head of Chagas Clinical Program, DNDi, Geneva

Review of recent preclinical information and pharmacokinetic-pharmacodynamic data in Chagas disease
Isabela Ribero, DNDi, Geneva
Biological markers of therapeutic response in Chagas disease – new developments
Igor Almeida, University of Texas El Paso, El Paso, United States
New treatment regimens of benznidazole – preclinical results and overview of planned studies
Joaquin Gascon, IS Global Barcelona Institute for Global Health, Barcelona, Spain
Nifurtimox for Chagas disease – recent clinical studies and perspectives
Jaime Altcheh, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

Chagas Coalition Symposium

Bridging the gap between patients and access to Chagas treatment: Lessons learned from scaling-up models in Latin America and the USA

Date: November 16
Chair: Peter Hotez, Baylor College of Medicine, Texas

Why treating Chagas should be a priority? Which are the access barriers to overcome?
Rafael Vilasanjuan, Barcelona Institute for Global Health
Chagas disease a global health problem in the USA: Gaps and challenges
Sheba Meymandi, Olive View, University of California, Los Angeles, Medical Center
Scaling up access to treatment: Lessons learned in endemic and non-endemic countries
Carolina Batista, DNDi, Rio
Scaling up access in Bolivia, the country with highest prevalence
Joaquin Gascon, IS Global Barcelona Institute for Global Health, Barcelona, Spain

 

Poster Session B

Date: November 15

Identification of new macrofilaricidal compounds for treatment of Onchocerciasis
Hübner MP, Hoerauf A, Townson S, Gokool S, Martin C, Chojnowski A, Kreiss T, Prorok M, Siekierka J, Khetani V, Zeldis J, Canan S, Scandale I, Hawryluk N
Impact of ivermectin mass treatment on the burden of onchocercal skin and eye disease: detailed model predictions through to 2025
Vinkeles Melchers NVS, Coffeng LE, Murdoch ME, Bakker R, Ozoh GA, Pedrique B, de Vlas SJ, Stolk WA

 

Poster Session C

Date: November 16

LB-5386 – Re-analysis of a sequential three-arm randomized trial of AmBisome in combination with sodium stibogluconate or miltefosine, and miltefosine monotherapy, for African visceral leishmaniasis
Alexander ND, Allison A, Edwards T,  Omollo R, Magirr D, Alves F, Musa A, Wasunna M

 

More information: